The Mark Of McClellan? Commissioner Downplays Role In Drug Approvals

FDA Commissioner McClellan's direct contribution to product reviews is limited to drawing on a network of outside experts to assist in decisions, the commissioner suggested during a May 16 Manhattan Institute-sponsored roundtable with buy-side analysts